Global X Robotics and Artificial Intelligence ETF vs Cardinal Health Inc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.87, while Cardinal Health Inc trades at $236.56 (market cap $55.88B). The key difference: Cardinal Health Inc pays a 0.86% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| BOTZ | CAH | |
|---|---|---|
52-Week High | $41.63 | $240.26 |
52-Week Low | $31.99 | $146.04 |
Market Cap | — | $55.88B |
Sector | — | Health |
Enterprise Value | — | $59.91B |
Dividend Yield | — | 0.86% |
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.92, up 1.34% with a bullish technical signal supported by moving averages. The robotics and AI ETF shows strong momentum with key resistance at $38. Recent articles highlight BOTZ as the largest pure-play robotics fund, positioned to benefit from the shift from digital to physical AI applications. The fund offers exposure to global robotics leaders with a lower expense ratio than peers.
Outlook remains positive as robotics adoption accelerates globally, though overbought RSI signals near-term caution. Investment opportunity lies in AI's expansion into physical automation, while risks include sector concentration and valuation pressures in tech. The fund's global diversification provides exposure to non-US AI innovation.
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →